Brief: Teva, Medincell Announce Positive Results For Risperidone Registration Trial

Medincell SA

07/01/2021 13:33

Jan 7 (Reuters) - Medincell SA  MEDCL.PA :
    * TEVA AND MEDINCELL ANNOUNCE POSITIVE RESULTS FOR
REGISTRATION
TRIAL OF INVESTIGATIONAL EXTENDED-RELEASE SUBCUTANEOUS
INJECTABLE RISPERIDONE FOR PATIENTS WITH SCHIZOPHRENIA
    * STUDY MET ITS PRIMARY EFFICACY ENDPOINT OF DELAYING TIME
TO
RELAPSE
    * NO NEW SAFETY SIGNALS HAVE BEEN IDENTIFIED THAT ARE
INCONSISTENT
WITH KNOWN SAFETY PROFILE OF OTHER RISPERIDONE FORMULATIONS
    * INTERIM RESULTS ALIGN WITH SAFETY FINDINGS OF RISE STUDY
    * SECOND OF TEVA'S PHASE 3 STUDIES (TV46000-CNS-30078 -
SHINE
STUDY) ACROSS 331 PATIENTS IS ONGOING

Source text for Eikon:  ID:nBw1DBw23a 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))